Clinical Trials for Head And Neck Cancer

A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For patients with unresectable locally advanced or metastatic HER2-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma that has progressed after one platinum/fluoropyrimidine-based regimen, this study compares sacituzumab tirumotecan plus paclitaxel with ramucirumab plus paclitaxel. Sacituzumab tirumotecan is an investigational TROP2-directed antibody–drug conjugate that delivers a topoisomerase I inhibitor.

ClinicalTrials.gov ID: NCT06445972

A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with unresectable locally advanced or metastatic upper gastrointestinal cancer receive investigational CHS-114, an anti-CCR8 antibody designed to deplete tumor-infiltrating regulatory T cells, plus the anti-PD-1 antibody toripalimab. Eligible groups include previously treated HER2-negative, MSS/pMMR gastric, gastroesophageal junction, or esophageal adenocarcinoma and previously treated esophageal squamous cell carcinoma (ESCC); untreated advanced ESCC receives the combination with 5-fluorouracil and cisplatin.

ClinicalTrials.gov ID: NCT06657144

Decentralized Pilot Study of Triple Oral Metronomic Chemotherapy for Patients With Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Adults with recurrent/metastatic oral cavity cancer after or ineligible for standard first-line immunotherapy/chemo-immunotherapy (ECOG 0–2) receive a fully oral metronomic regimen of methotrexate (antifolate), erlotinib (EGFR TKI), and celecoxib (COX‑2 inhibitor) in 28‑day cycles, delivered with decentralized/virtual components. Excludes significant cardiac risk, active serious infection/bleeding, uncontrolled viral hepatitis/HIV, pregnancy, and concurrent investigational therapy.

ClinicalTrials.gov ID: NCT06997068

A Phase 2 Trial of Intraoperative Fluorescent Angiography to Decrease Pharyngocutaneous Fistula Rates in Patients Undergoing Hypopharyngeal Reconstruction

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Adults with previously irradiated stage II–IV laryngeal or hypopharyngeal squamous cell carcinoma undergoing salvage total laryngectomy receive intraoperative indocyanine green (ICG) fluorescence angiography with the SPY system to assess mucosal perfusion, with resection of hypoperfused tissue prior to reconstruction. ICG is a near-infrared fluorescent dye used for real-time perfusion imaging, aiming to reduce postoperative pharyngocutaneous fistula, particularly in intraoperatively defined high-risk cases.

ClinicalTrials.gov ID: NCT06831149

A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors that have progressed after at least one systemic therapy receive FT836, an off-the-shelf, induced pluripotent stem cell–derived CAR T-cell therapy targeting MICA/MICB. FT836 is given alone or with paclitaxel, cetuximab, or trastuzumab, including paclitaxel–antibody combinations.

ClinicalTrials.gov ID: NCT07216105

A Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO-004 in Adults With Refractory/Recurrent Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, measurable metastatic or locally advanced head and neck, lung, gastrointestinal, pancreatic, cervical, endometrial, or urothelial cancer receive STRO-004 alone or with pembrolizumab. STRO-004 is a tissue factor–targeted antibody–drug conjugate that delivers the topoisomerase I inhibitor exatecan.

ClinicalTrials.gov ID: NCT07227168

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously untreated, locally advanced unresectable or metastatic esophageal squamous cell carcinoma and ECOG performance status 0–1 receive pembrolizumab plus an investigational antibody–drug conjugate, with or without chemotherapy, or pembrolizumab plus mFOLFOX6. The investigational agents are ifinatamab deruxtecan (B7-H3–targeted) and sacituzumab tirumotecan (TROP2-targeted), both of which deliver topoisomerase I inhibitors.

ClinicalTrials.gov ID: NCT06780111

A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-711 as a Monotherapy or in Combination With Budigalimab (ABBV-181) in Adult Subjects With Advanced Squamous Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced squamous tumors who have progressed after standard therapy or cannot receive it are eligible; expansion cohorts focus on squamous non-small cell lung cancer and head and neck squamous cell carcinoma. Treatment is oral ABBV-711, an investigational PARP7 inhibitor, alone or with intravenous budigalimab, an anti-PD-1 antibody.

ClinicalTrials.gov ID: NCT07241039

A Phase I Study of Zanzalintinib With Pembrolizumab and Cetuximab in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable recurrent or metastatic HNSCC not curable with local therapy, ECOG 0–1, and no more than two prior systemic lines receive oral zanzalintinib plus pembrolizumab and cetuximab; previously untreated patients must have PD-L1 CPS ≥1, and prior EGFR- or VEGFR-targeted therapy is excluded. Zanzalintinib is an investigational multikinase inhibitor targeting VEGFR2, MET, TYRO3, AXL, and MER.

ClinicalTrials.gov ID: NCT06912087

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, measurable MTAP-deleted advanced solid tumors (ECOG 0–1) receive oral IDE892 alone or with IDE397; dose-expansion cohorts are limited to NSCLC. IDE892 is an MTA-cooperative PRMT5 inhibitor, and IDE397 is a MAT2A inhibitor.

ClinicalTrials.gov ID: NCT07277413